Total Payments
$43,952
2024 Payments
$167.06
Companies
10
Transactions
121
Medicare Patients
245
Medicare Billing
$62,413
Payment Breakdown by Category
Other$38,148 (86.8%)
Travel$3,334 (7.6%)
Food & Beverage$2,402 (5.5%)
Education$68.33 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,148 | 26 | 86.8% |
| Travel and Lodging | $3,334 | 15 | 7.6% |
| Food and Beverage | $2,402 | 77 | 5.5% |
| Education | $68.33 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $23,804 | 55 | $0 (2023) |
| Allergan, Inc. | $9,077 | 17 | $0 (2020) |
| Ironshore Pharmaceuticals Inc. | $5,224 | 17 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $3,549 | 11 | $0 (2021) |
| ABBVIE INC. | $1,990 | 10 | $0 (2024) |
| Alkermes, Inc. | $201.50 | 5 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $47.39 | 3 | $0 (2023) |
| Arbor Pharmaceuticals, Inc. | $23.66 | 1 | $0 (2017) |
| Otsuka America Pharmaceutical, Inc. | $17.70 | 1 | $0 (2021) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.08 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $167.06 | 3 | ABBVIE INC. ($149.98) |
| 2023 | $46.35 | 2 | Supernus Pharmaceuticals, Inc. ($27.07) |
| 2022 | $299.26 | 19 | Supernus Pharmaceuticals, Inc. ($226.36) |
| 2021 | $25,561 | 52 | Supernus Pharmaceuticals, Inc. ($23,551) |
| 2020 | $4,227 | 4 | Allergan, Inc. ($3,527) |
| 2019 | $13,430 | 35 | Allergan Inc. ($5,489) |
| 2018 | $89.60 | 4 | Allergan Inc. ($61.49) |
| 2017 | $131.01 | 2 | Sunovion Pharmaceuticals Inc. ($107.35) |
All Payment Transactions
121 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $121.88 | General |
| Category: NEUROSCIENCE | ||||||
| 02/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: PSYCHIATRY | ||||||
| 01/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: NEUROSCIENCE | ||||||
| 08/09/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: PSYCHOLOGY | ||||||
| 02/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $12.34 | General |
| Category: PSYCHOLOGY | ||||||
| 11/10/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: CNS | ||||||
| 11/10/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $19.28 | General |
| Category: PSYCHOLOGY | ||||||
| 10/14/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $5.62 | General |
| Category: PSYCHOLOGY | ||||||
| 10/03/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: PSYCHOLOGY | ||||||
| 09/06/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $13.59 | General |
| Category: PSYCHOLOGY | ||||||
| 08/31/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $25.70 | General |
| Category: PSYCHOLOGY | ||||||
| 08/24/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $22.88 | General |
| Category: PSYCHOLOGY | ||||||
| 08/10/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: PSYCHOLOGY | ||||||
| 08/01/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $24.25 | General |
| Category: PSYCHOLOGY | ||||||
| 07/20/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $31.70 | General |
| Category: NEUROSCIENCE | ||||||
| 06/28/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $10.20 | General |
| Category: PSYCHOLOGY | ||||||
| 05/31/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $15.69 | General |
| Category: PSYCHOLOGY | ||||||
| 05/17/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: CNS | ||||||
| 05/05/2022 | Supernus Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $15.95 | General |
| 03/23/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $7.74 | General |
| Category: PSYCHOLOGY | ||||||
| 02/14/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $5.40 | General |
| Category: PSYCHOLOGY | ||||||
| 01/25/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| Category: PSYCHOLOGY | ||||||
| 01/24/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Education | In-kind items and services | $6.84 | General |
| Category: PSYCHOLOGY | ||||||
| 11/22/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.41 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 58 | 205 | $36,360 | $11,940 |
| 2022 | 4 | 83 | 363 | $81,460 | $27,027 |
| 2021 | 5 | 80 | 284 | $61,025 | $21,124 |
| 2020 | 2 | 24 | 55 | $6,760 | $2,322 |
Total Patients
245
Total Services
907
Medicare Billing
$62,413
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 11 | 61 | $10,900 | $3,840 | 35.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 42 | $8,150 | $3,389 | 41.6% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 22 | 65 | $10,440 | $3,000 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 37 | $6,870 | $1,712 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 85 | $37,980 | $11,608 | 30.6% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 30 | 130 | $18,130 | $6,144 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 75 | $13,630 | $5,863 | 43.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 73 | $11,720 | $3,413 | 29.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 45 | $19,130 | $6,154 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 65 | $13,795 | $5,206 | 37.7% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 13 | 68 | $12,790 | $4,296 | 33.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 52 | $7,915 | $2,747 | 34.7% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 22 | 54 | $7,395 | $2,721 | 36.8% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 13 | 28 | $3,000 | $1,357 | 45.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 27 | $3,760 | $964.93 | 25.7% |
About Dr. Brian Wise, MD
Dr. Brian Wise, MD is a Child & Adolescent Psychiatry healthcare provider based in Centennial, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1043211683.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Wise, MD has received a total of $43,952 in payments from pharmaceutical and medical device companies, with $167.06 received in 2024. These payments were reported across 121 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($38,148).
As a Medicare-enrolled provider, Wise has provided services to 245 Medicare beneficiaries, totaling 907 services with total Medicare billing of $62,413. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Other Specialties Psychiatry
- Location Centennial, CO
- Active Since 08/04/2005
- Last Updated 10/04/2024
- Taxonomy Code 2084P0804X
- Entity Type Individual
- NPI Number 1043211683
Products in Payments
- QELBREE (Drug) $21,241
- VRAYLAR (Drug) $11,067
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $5,224
- LATUDA (Drug) $3,549
- LYBALVI (Drug) $166.57
- ARISTADA (Drug) $34.93
- Trintellix (Drug) $28.11
- Evekeo (Drug) $23.66
- TRINTELLIX (Drug) $19.28
- REXULTI (Drug) $17.70
- CAPLYTA (Drug) $17.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Centennial
Mr. Donald Jacobs, Md, MD
Child & Adolescent Psychiatry — Payments: $440.42
Child & Adolescent Psychiatry $440.42
Dr. Barbara Rose, Md, MD
Child & Adolescent Psychiatry
Child & Adolescent Psychiatry
Sarah Warren, M.d, M.D
Child & Adolescent Psychiatry
Child & Adolescent Psychiatry
Dr. Louis Fine, M.d, M.D
Child & Adolescent Psychiatry
Child & Adolescent Psychiatry